Literature DB >> 11239447

CTLA-4 regulates induction of anergy in vivo.

R J Greenwald1, V A Boussiotis, R B Lorsbach, A K Abbas, A H Sharpe.   

Abstract

The requirement for CTLA-4 during the induction of peripheral T cell tolerance in vivo was investigated using naive TCR transgenic T cells lacking CTLA-4. CTLA-4(-/-) T cells are resistant to tolerance induction, as demonstrated by their proliferative responses, IL-2 production, and progression into the cell cycle. Following exposure to a tolerogenic stimulus in vivo and restimulation in vitro, wild-type T cells are blocked at the late G1 to S restriction point of the cell cycle. In contrast, CTLA-4(-/-) T cells enter into the S phase of the cell cycle, as shown by downregulation of p27(kip1), elevated cdk2 kinase activity, and Rb hyperphosphorylation. Thus, CTLA-4 has an essential role in determining the outcome of T cell encounter with a tolerogenic stimulus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239447     DOI: 10.1016/s1074-7613(01)00097-8

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  120 in total

1.  Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy.

Authors:  A D Wells; M C Walsh; J A Bluestone; L A Turka
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  T-cell activation occurs simultaneously in local and peripheral lymphoid tissue following oral administration of a range of doses of immunogenic or tolerogenic antigen although tolerized T cells display a defect in cell division.

Authors:  Karen M Smith; Joanne M Davidson; Paul Garside
Journal:  Immunology       Date:  2002-06       Impact factor: 7.397

3.  Auto-antibody production and glomerulonephritis in congenic Slamf1-/- and Slamf2-/- [B6.129] but not in Slamf1-/- and Slamf2-/- [BALB/c.129] mice.

Authors:  Marton Keszei; Yvette E Latchman; Vijay K Vanguri; Daniel R Brown; Cynthia Detre; Massimo Morra; Carolina V Arancibia-Carcamo; Carolina V Arancibia; Elahna Paul; Silvia Calpe; Wilson Castro; Ninghai Wang; Cox Terhorst; Arlene H Sharpe
Journal:  Int Immunol       Date:  2011-01-28       Impact factor: 4.823

Review 4.  T-cell anergy: from phenotype to genotype and back.

Authors:  Christine M Seroogy; C Garrison Fathman
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 5.  Highly specialized role of Forkhead box O transcription factors in the immune system.

Authors:  Anne S Dejean; Stephen M Hedrick; Yann M Kerdiles
Journal:  Antioxid Redox Signal       Date:  2010-12-13       Impact factor: 8.401

Review 6.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok; James P Allison
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

7.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.

Authors:  Josef Kurtz; Forum Raval; Casey Vallot; Jayden Der; Megan Sykes
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

8.  PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.

Authors:  Vrajesh V Parekh; Saif Lalani; Sungjune Kim; Ramesh Halder; Miyuki Azuma; Hideo Yagita; Vipin Kumar; Lan Wu; Luc Van Kaer
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 9.  Emerging Systemic Therapies for Colorectal Cancer.

Authors:  Christine M Veenstra; John C Krauss
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

Review 10.  Induction and stability of the anergic phenotype in T cells.

Authors:  Rut Valdor; Fernando Macian
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.